RYET to Enter Malaysian Healthcare Through Exclusive Cogni AI License to BioNexus Gene Lab
License of up to 20 years and reciprocal share exchange would entitle RYET to a 10% royalty on qualifying technology receipts and 560,000 BGLC shares as Malaysia accelerates public healthcare digitalization License of up to 20 years and reciprocal share exchange would entitle RYET to a 10% royalty on qualifying technology receipts and 560,000 BGLC shares as Malaysia accelerates public healthcare digitalization
Covered in this story
Call it yourself
No calls on $RYET yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Ruanyun Edai Technology →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.